Mangrove Partners Cue Biopharma, Inc. Call Options Transaction History
Mangrove Partners
- $890 Million
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CUE
# of Institutions
65Shares Held
15.3MCall Options Held
56.1KPut Options Held
11.1K-
Bleichroeder LP New York, NY5MShares$9.39 Million1.28% of portfolio
-
Slate Path Capital LP New York, NY2.4MShares$4.52 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.03MShares$3.82 Million0.0% of portfolio
-
Black Rock Inc. New York, NY757KShares$1.42 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA509KShares$956,5940.0% of portfolio
About Cue Biopharma, Inc.
- Ticker CUE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,381,700
- Market Cap $66.5M
- Description
- Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...